On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...